LIXTE Biotechnology Holdings to Present at Planet MicroCap Showcase: VIRTUAL 2022 Investor Conference

LIXTE Biotechnology Holdings, Inc. (Nasdaq:LIXT) today announced it will be presenting at the Planet MicroCap Showcase: VIRTUAL 2022 investor conference Wednesday, December 7, 2022 at 3:30 p.m. EST/12:30 p.m. PST.

John S. Kovach, M.D., founder and CEO of LIXTE, will host the presentation. Dr. Kovach, with his team, will be answering questions at the conclusion.

To access the presentation, please use the following information:

Planet MicroCap Showcase: VIRTUAL 2022

Date: Wednesday, December 7, 2022
Time: 3:30 p.m. EST/12:30 p.m. PST
Webcast: https://www.webcaster4.com/Webcast/Page/2937/47232

LIXTE is a drug discovery company that has a developed unique, proprietary, first in-class protein phosphatase inhibitor, LB-100, as its lead clinical compound. LB-100 has potential widespread use as an anti-cancer agent when used alone and in combination with standard anti-cancer therapies, including cytotoxic drugs, radiation, and immune checkpoint blockers.

To view LIXTE Biotechnology Holdings` presentation at the Planet MicroCap conference, register in advance at: https://planetmicrocapshowcase.com/signup

The Planet MicroCap Showcase: VIRTUAL 2022 website is available at https://planetmicrocapshowcase.com/

All company presentations as part of the conference will be available directly on the conference event platform on this link under the tab "Agenda" at: https://planetmicrocapshowcase.com/agenda

About LIXTE Biotechnology Holdings
LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. Major drivers of cancer are defects in the switches that turn the biochemical pathways in cells on or off. Most cancer research over the past 30 years has focused on the "on" switches because the "off" switches, especially the master "off" switch protein phosphatase (PP2A), were believed to cause intolerable toxicity in patients. LIXTE has achieved a breakthrough with its novel, first-in-class lead clinical compound and PP2A inhibitor, LB-100, demonstrating that LB-100 is readily tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data (see www.lixte.com), LB-100 has the potential to significantly improve outcomes for patients undergoing various chemotherapies or immunotherapies. LIXTE`s new approach has no known competitors and is covered by a comprehensive patent portfolio. Initial proof-of-concept clinical trials are in progress.

About Planet MicroCap
Planet MicroCap is a global multimedia and publishing financial news investor portal specifically focused on covering the MicroCap market by providing news, insights, education tools and expert commentary. Planet MicroCap has cultivated an active and engaged community that is interested in learning about and staying ahead of the curve in the MicroCap space.